
HTGF backs €7m seed round for Zimmer Biotech
High-Tech Gründerfonds (HTGF) has invested in a €7m seed round for the spin-out of Zimmer Biotech along with the company's parent, medical device producer Zimmer Medizinsysteme.
Zimmer Biotech will focus on developing a skin cancer drug based on the compound 5-Aminolevulinic acid.
The spinout has put a quality-management system in place to gain the necessary legal accreditation and aims to test its drug on humans in clinical trials starting in 2020.
Parent company Zimmer Medizinsysteme is a medical device producer based in Neu-Ulm. It employs 250 people and markets its products in 80 countries.
Company
Zimmer Medizinsysteme began development of a drug based on the compound 5-Aminolevulinic acid in 2012 but the spinout was not officially established until October 2016.
Zimmer Biotech develops Alevin Deep, a drug for use in the treatment of actinic keratosis, which can lead to skin cancer. The company says it will reduce treatment time and the pain associated with the treatment.
People
High-Tech Gründerfonds – Frank Hensel (senior investment manager).
Zimmer Medizinsysteme – Armin Zimmer (president).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater